Coverage of the 46th Annual Meeting of the European Association for the Study of the Liver

March 30 - April 3, 2011, Berlin, Germany

The material posted on HIVandHepatitis.com is not approved by nor is it a part of EASL 2011.

Hepatitis C Articles

• EASL Releases New Hepatitis C Clinical Practice Guidelines
• Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C
• Tegobuvir Works Well in Triple and Quad Regimens for HCV
• Boosted Danoprevir Improves Response in Prior Null Responders
• Once-Daily BI201335 Ups Response to Interferon for Hepatitis C
• BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
• Statin Boosts Response to Pegylated Interferon/Ribavirin
• Boceprevir Helps Hepatitis C Patients with Cirrhosis
• TMC435 Beats Standard Therapy Regardless of HCV Genotype
• Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
• Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
• Pegylated Interferon Lambda Boosts Response with Few Side Effects
• First Sustained Response Data for Polymerase Inhibitor Mericitabine
• 4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
• Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
• BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
• Cyclophilin Inhibitor Alisporivir Active Against HCV in Phase 2b, HBV in Lab

Hepatitis B Articles

• Kidney Toxicity Uncommon among People Taking Tenofovir for Hepatitis B
• HBV Genotype Predicts HBeAg Seroconversion on Tenofovir
• Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B

Library of Slides and Posters

• Baseline Genotype And HBsAg Were Found To Have Signifi cant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment
  J Heathcote and others. EASL 2011.
• Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist
  D Tumas and others. EASL 2011.
• Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees
  R Lanford and others. EASL 2011.
• Anti-Viral Effi cacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection
  S Menne and others. EASL 2011.
• Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon a-2a and Ribavirin in the PILLAR Study
  J Aerssens and others. EASL 2011.
• Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin
  O Lenz and others. EASL 2011.
• Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment
  V Sekar and others. EASL 2011.
• The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis
  S Zeuzem and others. EASL 2011.
• First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects
  S Pol and others. EASL 2011.
• A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection
  E Lawitz and others. EASL 2011.
• Interim Results of a Randomized Treatment Study of Emtricitabine/Tenofovir DF (FTC/TDF) and HBIG Withdrawal in Post-Orthotopic Liver Transplant (OLT) Recipients for CHB
  L Tepperman and others. EASL 2011.
• Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451
  A Corsa and others. EASL 2011.
• Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA) Assessments in Patients with Chronic Hepatitis B (CHB)
  S Fung and others. EASL 2011.
• Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies
  P Marcellin and others. EASL 2011.
• A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects
  U Lopatin and others. EASL 2011.
• HBsAg Kinetics in Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumurate (TDF) for up to 4 years
  P Marcellin and others. EASL 2011.